



Scientific Steering Committee and Invited Speaker Biographies

Scientific Steering Committee



Tanya Agurs-Collins, Ph.D., R.D.

Dr. Tanya Agurs-Collins is a Program Director in the Health Behaviors Research Branch of the Behavioral Research Program, Division of Cancer Control and Population Sciences, at the National Cancer Institute (NCI). In this capacity, she is responsible for directing, coordinating, and managing a research grant portfolio in diet, physical activity, and weight loss behavioral interventions for cancer prevention and survival. Dr. Agurs-Collins’s research focuses on race and ethnic disparities in dietary intake and obesity on cancer risk and survival. She is also interested in understanding individual genetic variation in diet and physical activity behaviors and response to weight loss interventions.

Dr. Agurs-Collins has a Ph.D. in Nutritional Sciences with an emphasis in epidemiology and a master’s degree in Public Health Nutrition from the Pennsylvania State University in University Park, Pennsylvania. She also holds a bachelor’s degree in Nutrition and Dietetics from Howard University in Washington, D.C. Prior to joining NCI, Dr. Agurs-Collins was an Associate Professor in the Department of Medicine at Howard University College of Medicine and a nutritional epidemiologist at the Howard University Cancer Center. She is a registered dietitian with the Academy of Nutrition and Dietetics.



Tim Ahles, Ph.D.

Dr. Tim Ahles received his Ph.D. (1982) in Clinical Psychology from the State University of New York at Albany and completed his internship at the University of Mississippi Medical Center. While on faculty at the Department of Psychiatry of Dartmouth Medical School he developed and directed the Center for Psycho-Oncology Research (1992-2006), which focused on quality of life and symptom management research in cancer patients. In April 2006, he moved to Memorial Sloan Kettering Cancer Center to develop and direct the Neurocognitive Research Laboratory.

Over the last 25 years, his research has focused on cognitive side effects of chemotherapy in patients with breast cancer and lymphoma. These studies have included cross-sectional and longitudinal studies of chemotherapy-induced cognitive change utilizing neuropsychological assessments and structural and functional MRI, examination of genetic factors and biomarkers that increase risk for cognitive changes, study of the interface of treatment-induced cognitive change and aging, the evaluation of cognitive behavioral interventions, and collaborative translational animal model studies designed to identify mechanisms of chemotherapy-induced cognitive change.



Judith Campisi, Ph.D.

Dr. Judith Campisi received a Ph.D. in Biochemistry from the State University of New York at Stony Brook, and postdoctoral training in cell cycle regulation at the Dana-Farber Cancer Institute and Harvard Medical School. As an Assistant Professor at the Boston University Medical School, she studied the role of cellular senescence in suppressing cancer, and soon became convinced that senescent cells also contributed to aging. She left Boston University as an Associate Professor to become a Senior Scientist at the Lawrence Berkeley National Laboratory in 1991. In 2002, she started a second laboratory at the Buck Institute for Research on Aging, where she is a Professor. At both institutions, Dr. Campisi established a broad program to understand the relationship between aging and age-related disease, with an emphasis on the interface between cancer and aging. Her laboratory made several pioneering discoveries in these areas, and her research continues to challenge and alter existing paradigms. In recognition of her research and leadership, Dr. Campisi received numerous awards, including two MERIT awards from the National Institute on Aging, awards from the AlliedSignal Corporation, Gerontological Society of America, and American Federation for Aging Research, the Longevity prize from the IPSEN Foundation, the Bennett Cohen award from the University of Michigan, the Schober award from Halle University, and the first international Olav Thon Foundation prize. She is an elected fellow of the American Association for the Advancement of Science and serves on numerous national and international editorial and scientific advisory boards.



Rebecca Fuldner, Ph.D.

Dr. Rebecca Fuldner is a cellular and molecular biologist. She received her undergraduate degree in Biochemistry from the University of California, Berkeley, and a Ph.D. from the University of Wisconsin in Madison, Wisconsin. After spending five years as a senior staff fellow studying T cell activation in the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, she joined The Institute for Genomic Research (TIGR) in Rockville, Maryland, and became familiar with various genomic approaches for gene discovery. The most challenging project she encountered while at TIGR was related to candidate gene identification for early onset Alzheimer's disease. In 1999, Dr. Fuldner returned to the National Institutes of Health (NIH), and she is currently the branch chief of the Aging Physiology Program within the Division of Aging Biology at the National Institute on Aging at NIH. Her portfolio includes research related to understanding the basis for senescence of the immune system in older individuals and therefore includes studies on the function of both the innate and adaptive immune systems in the elderly. In addition, her portfolio includes studies on vaccine effectiveness in elderly adults.



Lisa Gallicchio, Ph.D.

Dr. Lisa Gallicchio is a Program Director in the Clinical and Translational Epidemiology Branch (CTEB) of the Epidemiology and Genomics Research Program (EGRP) at the National Cancer Institute (NCI). She is involved in research efforts to identify clinical and genomic factors that influence cancer treatment outcomes, including those factors that may contribute to observed disparities in health outcomes.

Prior to joining EGRP, Dr. Gallicchio was a Senior Epidemiologist in The Prevention and Research Center in the Weinberg Center for Women's Health & Medicine at Mercy Medical Center. During this time, she also served as an Adjunct Assistant Professor in the University

of Maryland at Baltimore Department of Epidemiology and Public Health and the Johns Hopkins University Bloomberg School of Public Health Department of Epidemiology.

Dr. Gallicchio's work at Mercy Medical Center involved overseeing studies aimed at better understanding long-term health outcomes of cancer survivors as well as factors associated with cancer treatment adherence. She was the Principal Investigator of a cohort study examining racial differences in the cardiovascular health effects of aromatase inhibitors, a hormonal therapy commonly used among breast cancer patients. Dr. Gallicchio's research specialties also include clarifying factors that underlie the conditions affecting the health of women during midlife. She has a particular interest in health disparities.



Paige A. Green, Ph.D., M.P.H., F.A.B.M.R.

Dr. Paige A. Green is Chief of the Basic Biobehavioral and Psychological Sciences Branch in the Behavioral Research Program, Division of Cancer Control and Population Sciences, at the National Cancer Institute (NCI). Her NCI career has focused on cultivating research that generates fundamental knowledge of behavioral, biobehavioral, and psychological science mechanisms and elucidates their translational relevance for cancer prevention and control. Recent initiatives include the NCI Network on Biobehavioral Pathways in Cancer.

Dr. Green received her doctorate in Clinical Psychology from the University of Miami in Coral Gables, Florida. In 2005, she received a Master of Public Health degree from Bloomberg School of Public Health at Johns Hopkins University. After working as an assistant professor of medicine at the Howard University College of Medicine and a research psychologist at HUCC, she joined the Behavioral Research Program as a program director in 2001, and she has been branch chief since 2007.

Dr. Green is an elected fellow and secretary of the Academy of Behavioral Medicine Research and a member and past leader of the American Psychosomatic Society. She has served as editorial board member, guest editor, and manuscript reviewer for a variety of peer-reviewed journals. Dr. Green has received the National Institutes of Health (NIH) Awards of Merit for the NIH Genes, Environment and Health Initiative (2012); the NIH Basic Behavioral and Social Science Opportunity Network (2012); and leadership of basic behavioral science at NCI and NIH (2013). In 2015, Dr. Green was selected as one of five federal servants to receive the 2015 Meritorious Research Service Commendation from the American Psychological Association Board of Scientific Affairs.



Jennifer Guida, Ph.D., M.P.H.

Dr. Jennifer Guida is a Postdoctoral Fellow in the Basic Biobehavioral and Psychological Sciences Branch in the Behavioral Research Program, Division of Cancer Control and Population Sciences, at the National Cancer Institute. Dr. Guida is interested in factors that impact quality of life for cancer survivors, including the intersection of aging, psychosocial and contextual factors, and late emerging treatment effects.

Dr. Guida completed her doctoral degree in Epidemiology from the University of Maryland, College Park and a Master's in Public Health (M.P.H.) from the University of Colorado. During her M.P.H. training, she was a fellow at the Centers for Disease Control and Prevention in Atlanta, Georgia, in the National Center for HIV/AIDS, viral Hepatitis, STD, and TB Prevention in the Office of the Director. During her doctoral training, Dr. Guida became a Research

Fellow in the Genetic Epidemiology Branch in the Division of Cancer Epidemiology and Genetics.

Kevin Howcroft, Ph.D.

Dr. Kevin Howcroft is chief of the Cancer Immunology, Hematology, and Etiology Branch of the National Cancer Institute's Division of Cancer Biology.

Chamelli Jhappan, Ph.D.

Dr. Chamelli Jhappan is a program director in the Cancer Immunology, Hematology, and Etiology Branch of the National Cancer Institute's Division of Cancer Biology.



Ronald Kohanski, Ph.D.

Dr. Ronald Kohanski is the Deputy Director of the Division of Aging Biology at the National Institute on Aging (NIA). Trained as a biochemist, he obtained a Ph.D. in Biochemistry from the University of Chicago in 1981. After a postdoctoral fellowship with M. Daniel Lane at the Johns Hopkins University School of Medicine, he held a faculty position at the Mount Sinai School of Medicine for 17 years before returning as a faculty member at Johns Hopkins. His fields of research included enzymology and developmental biology of the insulin receptor. Dr. Kohanski joined the Division of Aging Biology, NIA, in 2005 as a Program Officer, and became Division Deputy Director in 2007. Dr. Kohanski has promoted aging research in the specific areas of stem cell biology and cardiovascular biology. More broadly, he promotes research efforts to expand studies beyond laboratory animals, to address the basic biology of aging explicitly in human populations and non-laboratory animals (domestic and wild populations).

Dr. Kohanski is also a co-founder and co-leader of the trans-NIH Geroscience Interest Group (GSIG). The group spans the entire NIH and is built on the premise that aging is the major risk factor for most chronic age-related diseases. In keeping with this program, Dr. Kohanski has encouraged researchers to consider age as an essential parameter of research using animal models of chronic diseases. More broadly, he promotes research into the basic biology of aging that could explain why aging is itself the major risk factor for chronic diseases.



Supriya Mohile, M.D., M.S.

Dr. Supriya Gupta Mohile is a board-certified geriatrician and oncologist and is the Wehrheim Professor of Medicine at the University of Rochester. Dr. Mohile has developed a clinical and research program in geriatric oncology by strengthening the links between geriatrics and oncology. She completed internship, residency and fellowships in hematology/oncology and geriatrics at University of Chicago Medical Center, where she also earned a Master's degree in health outcomes research. Her fellowship was funded by an American Society of Clinical Oncology (ASCO) and John Hartford Foundation initiative to train oncologists in the care of older patients. Dr. Mohile's research interests include the evaluation of patterns of care, health outcomes, and quality of life related to treatment for cancer in older patients. Her early research was funded by a Hartford Geriatric Health Outcomes Research Award and a GEMSTAR award from the National Institute on Aging (NIA). In 2013, she was awarded a Patient Centered Outcomes Research Institute Award and a National Cancer Institute (NCI) R01 to evaluate whether geriatric assessment can improve outcomes of older patients with cancer. She is an integral member of the University of

Rochester NCI Community Oncology Research Program (NCORP) Research Base, which is directed by Dr. Gary Morrow. She leads the Cancer Care Delivery Research (CCDR) efforts in the Research Base. Dr. Mohile is an expert in geriatric oncology with over 150 publications. She is Editor-in-Chief of the *Journal of Geriatric Oncology*. She was the Chair for the ASCO Geriatric Oncology Clinical Guideline panel, and she received ASCO's BJ Kennedy Award in 2018. In 2018, Dr. Mohile was awarded an NIA R21/R33 grant with Drs. William Dale and Arti Hurria to build a national infrastructure for geriatric oncology research and an NIA K24 that provides her with 50% effort to collaborate with investigators pursuing geriatric oncology research and leadership. Through currently funded projects that support patient-oriented research in geriatric oncology and the NCORP Research Base, Dr. Mohile has the resources to foster and support the careers of investigators interested in geriatric oncology research.



Kirsten K. Ness, P.T., Ph.D., F.A.P.T.A.

Dr. Kirsten K. Ness is a physical therapist and clinical epidemiologist and Member of the faculty at St. Jude Children's Research Hospital. She has a B.A. in Physical Therapy, an M.A. in Leadership, and an M.P.H. and Ph.D. in Epidemiology. She is a Catherine Worthingham Fellow of the American Physical Therapy Association and has been in Physical Therapy practice for over 30 years. Her research focuses on the observation and remediation of functional loss among persons who were treated for cancer during childhood. She has funding from the American Cancer Society, the Gabrielle's Angel Foundation, the National Cancer Institute, and the National Institute of Child Health and Human Development. She has over 200 peer-reviewed publications and serves on the Steering Committees for the Childhood Cancer Survivor Study and the Children's Oncology Group Survivorship and Outcomes Committee. She is an active member of the Oncology Section of the American Physical Therapy Association, and on the Editorial Boards of *Pediatric Physical Therapy*, *Pediatric Blood & Cancer*, *Physical Therapy*, *Rehabilitation Oncology*, and the *Journal of Clinical Oncology*.



Ann O'Mara, Ph.D., R.N.

Dr. Ann O'Mara recently retired as Head of Palliative Research at the National Cancer Institute (NCI) Division of Cancer Prevention. She managed a portfolio of symptom management and palliative and end-of-life care research projects. The majority of these projects focused on the more common morbidities associated with cancer and its treatment, e.g., pain, chemotherapy-induced neuropathy, fatigue, sleep disturbances, and psychosocial issues, such as distress, anxiety, and depression. She was a member of several trans-NIH working groups and consortia, e.g., trans-NIH Pain Consortium, established to enhance research and promote collaboration across NIH Institutes and Centers with programs and activities addressing morbidities. Dr. O'Mara conducted research on end-of-life care, and on educating nurses and physicians about palliative care. Her publications focus on quality-of-life issues facing cancer patients and families across the disease trajectory. Prior to NCI, she was Director of the Advanced Practice Oncology Track, University of Maryland School of Nursing. She is a member of the Oncology Nursing Society, American Society of Clinical Oncology, American Nurses Association, American Pain Society, and International Society for Quality of Life Research; a Fellow in the American Academy of Nursing; and a former editorial board member of the *Journal of Clinical Oncology*. She received numerous NIH merit awards for efforts promoting symptom management and quality-of-life research. She received the Distinguished Alumni Award from the University at Buffalo, the State University

of New York, where she received a B.S. in Nursing. She earned an M.S. in Nursing from the Catholic University of America, a Master of Public Health from the Uniformed Services University of the Health Sciences, and a Ph.D. from the University of Maryland, College Park.



Frank Perna, Ed.D., Ph.D.

Dr. Frank Perna is a Psychologist and Program Director in the Health Behaviors Research Branch of the Behavioral Research Program, Division of Cancer Control and Population Sciences (DCCPS), at the National Cancer Institute (NCI). Dr. Perna provides leadership and oversees a research portfolio related to physical activity promotion, exercise intervention for cancer survivors, and skin cancer prevention and control. He holds a secondary appointment with the DCCPS Implementation Science team.

Prior to coming to NCI, Dr. Perna was a tenured associate professor at West Virginia University and later served as an associate professor and director of health psychology at Boston University School of Medicine, where he maintained an active program of NIH-funded research and a clinical practice. Throughout his career, his work has addressed exercise intervention for persons with or at risk for chronic disease. His other research and practice areas include performance enhancement work with professional and recreational athletes, facilitating adjustment to athletic injury, and skin cancer prevention and control.

Dr. Perna has been listed on the Sport Psychology Registry of the United States Olympic Committee. He served as a research psychologist at the 1996 Olympic Games in Atlanta, Georgia. He was elected to the executive boards of the Association of Applied Sport Psychology and the American Psychological Association's Division of Exercise & Sport Psychology, and he served on the editorial board for the Journal of Applied Sport Psychology and on two Commonwealth of Massachusetts Expert Panels on the Safety of Bariatric Surgery. He was also the recipient of the Dorothy Harris Early Career Contribution award and the Walter Peach Health Psychology career award from the Association of Applied Sport Psychology. He received his Bachelor's degree from the East Stroudsburg University, obtained Doctorates in Counseling Psychology and Health Psychology from Boston University and the University of Pittsburgh, respectively, and completed a clinical psychology internship in medical psychology at the Boston Veterans Administration Medical Center. He also held postdoctoral fellowships at the U.S. Olympic Training Center and the University of Miami.



Jennifer Schrack, Ph.D., M.S.

Dr. Jennifer Schrack is an Associate Professor of Epidemiology at Johns Hopkins University with a primary research focus on the role of physiological factors in maintaining mobility and functional independence with aging. She holds a Master's in Exercise Physiology from the University of Michigan and a Ph.D. in Epidemiology from the Johns Hopkins Bloomberg School of Public Health. She has extensive clinical and research experience as an exercise physiologist, with an emphasis on the assessment of laboratory measures of energy expenditure and free-living physical activity using accelerometers. This work has grown to include multiple types of activity and heart rate monitors across numerous studies, including the Baltimore Longitudinal Study of Aging (BLSA), the Study of Physical Resiliency in Geriatrics (SPRING), the Study to Understand vitamin D and falls in You (STURDY), the Aging, Cognition, and Hearing Evaluation in Elders (ACHIEVE) Randomized Trial, and the Multicenter AIDS Cohort Study (MACS). Her recent research has expanded to include assessment of physiological mechanisms contributing to the development of an accelerated

aging phenotype. She recently completed a K01 award from the National Institute on Aging (NIA) focused on investigating differences in functional decline, energy expenditure, and physical activity by HIV-serostatus in the MACS. She is currently the PI of a R21 from the NIA to investigate mechanisms of fatigability in participants of the BLSA, overall and by cancer history, and of a U01 from the NIA to delineate associations among energy regulation, physical activity, and Alzheimer's disease in the BLSA.



Felipe Sierra, Ph.D.

Dr. Felipe Sierra is the Director of the Division of Aging Biology at the National Institute on Aging (NIA). Trained as a biochemist in his native Chile, he obtained a Ph.D. in Biochemistry and Molecular Biology from the University of Florida in 1983. After a postdoc at the University of Geneva, he worked in industry (at Nestlé, still in Switzerland) for the next five years. At this stage he developed his interest in the biology of aging, an interest that brought him back to academia (and to the United States), as an Assistant Professor at the Medical College of Pennsylvania, and later as an Associate Professor at the Lankenau Institute for Medical Research in Pennsylvania. This last position was shared with a primary appointment at the University of Chile in Santiago. Four years after initiating this arrangement, Dr. Sierra relocated again to the U.S., this time as a Program Director within the Division of Aging Biology, NIA. He became the Director of this unit in April 2006.

Dr. Sierra is also the founder and coordinator of the trans-NIH Geroscience Interest Group (GSIG). The group spans the entire NIH and is built on the fact that aging is the major risk factor for most chronic age-related diseases – Alzheimer's, cardiovascular disease, cancer, and more – and thus understanding the basic biology of aging is central to our ability to address these diseases. In 2013 and 2014 he received NIH Director's Awards for this effort.



Russell Tracy, Ph.D.

Dr. Russell Tracy is a Professor in the Department of Pathology & Laboratory Medicine in the University of Vermont's Larner College of Medicine. His approach to research reflects his training in biochemistry and clinical chemistry, and his long interest in population-based science. Areas of research include the interrelationships of coagulation, fibrinolysis, and inflammation, especially the innate and adaptive immune systems, in the etiology of atherosclerosis and coronary heart disease, insulin resistance and diabetes, HIV-related morbidity and mortality, and other complex diseases, as well as more broadly in the process of aging. The main tools of his laboratory are those of molecular and genetic epidemiology, in the context of multicenter studies and clinical research. More basic biochemical approaches are used in the development of new assays for epidemiological application. Dr. Tracy has a longstanding interest in disease risk modeling and risk assessment as well as in developing new biomarkers for clinical and epidemiological research.

Invited Speakers



William Dale, M.D., Ph.D.

Dr. William Dale is a board-certified geriatrician and palliative medicine internist with a Ph.D. in health policy. He currently serves as Chair of the Department of Supportive Care Medicine at City of Hope. His clinical and scholarly work is devoted to geriatric oncology, with a focus on medical decision-making, behavioral economics, care models, and quality of life in older adults with cancer. In 2006, he established the award-winning Specialized Oncology Care & Research in the Elderly (SOCARE) clinic, a geriatric-oncology clinic embedded in oncology at the University of Chicago. This specialized program offers interdisciplinary, individualized, and integrated treatment for older patients and survivors with cancer. SOCARE partnered closely with a sister clinic at the University of Rochester. Dr. Dale is a national leader in geriatric oncology, with over 110 publications supported by funding from the National Institute on Aging (NIA), the National Cancer Institute, the American Cancer Society, the Hartford Foundation, the Coleman Foundation, and the Foundation for Informed Medical Decision Making, among others. He collaborates widely on interdisciplinary research that integrates the clinical and social sciences, particularly through the Cancer & Aging Research Group (CARG). He is the lead PI, along with Drs. Arti Hurria and Supriya Mohile, on a recently awarded R21/R33 NIA grant, "Geriatric Oncology Research Infrastructure to Improve Clinical Care."



Wendy Demark-Wahnefried, Ph.D., R.D.

Dr. Wendy Demark-Wahnefried is Professor and Webb Endowed Chair of Nutrition Sciences at the University of Alabama at Birmingham (UAB) School of Health Professions. Dr. Demark-Wahnefried began her career as a cancer researcher at Duke University, where she was on faculty for 17 years, then was recruited to MD Anderson, and then joined UAB in 2010 as the Associate Director for Cancer Prevention and Control in the Cancer Center. Her research in nutrition and cancer control and survivorship has produced close to 300 scientific publications. Early in her career and through a K07 award, she uncovered evidence of rapid onset adverse body composition changes (sarcopenic obesity) in women receiving adjuvant chemotherapy for breast cancer (vs. localized treatment). These data, plus proof of concept pilot data showing that these changes could be mitigated via resistance training exercise within a healthy lifestyles intervention, won her recognition as a Komen Professor of Survivorship. Later in her career she led large-scale trials, such as Reach-Out to ENhance Wellness in Older Cancer Survivors: RENEW (n=641), aimed at testing home-based, diet and exercise approaches to improve diet quality, physical activity, weight status, and physical functioning among older cancer survivors (now being further optimized under the Adapting MultiPLe behavior Interventions that effectively Improve (AMPLIFI) Cancer Survivor Health P01CA214651), as well as clinically intensive presurgical trials to test the impact of weight loss intervention on tumor proliferation rates, as well as other biomarkers. Dr. Demark-Wahnefried is an American Cancer Society Clinical Research Professor and serves or has served on several committees, including the American Cancer Society's Guidelines Panel for Nutrition and Physical Activity, World Cancer Research Fund, American College of Sports Medicine Guidelines Panel for Physical Activity in Cancer Survivors, American Society of Clinical Oncology Committee on Cancer Survivorship and Energy Balance, and the National Cancer Policy Forum of the National Academy of Sciences, Engineering, and Medicine.



Jorg Dietrich, M.D., Ph.D., M.M.Sc., F.A.A.N.

Dr. Jorg Dietrich is the Director of the Cancer & Neurotoxicity Clinic and Brain Repair Research Program at the Massachusetts General Hospital (MGH) Cancer Center, Attending Physician at MGH, and Assistant Professor of Neurology at Harvard Medical School.

His clinical interests are management of patients with benign and malignant brain tumors and neurologic complications of cancer therapy, including toxicity from radiation and chemotherapy. His research activities include clinical, translational, and basic research in the fields of brain tumor biology, biomarkers of cancer, neurotoxicity from cancer therapies, and brain repair mechanisms.

Dr. Dietrich is the author of over 150 publications, including original research articles, review papers, book chapters, and other scientific contributions. His work has been supported by the National Institutes of Health, the American Cancer Society, the American Academy of Neurology, and other foundations.



Paul Jacobsen, Ph.D.

Dr. Paul Jacobsen is the Associate Director of the NCI Division of Cancer Control and Population Science's (DCCPS) Healthcare Delivery Research Program (HDRP). In this position, he leads a team at NCI whose mission is to serve as a catalyst for the field of health care delivery research and to enhance data resources, measures, and NCI's grant portfolio in this domain. He also plays a key role in NCI's collaborations with other agencies and organizations in health services and outcomes research.

Dr. Jacobsen came to NCI from the Moffitt Cancer Center, where he served as founding Chair of Moffitt's Department of Health Outcomes and Behavior and subsequently as Associate Center Director for Population Science. Over the course of 30 years, his research has focused on patient-centered health outcomes, behavioral aspects of cancer prevention and detection, and supportive care medicine. He has worked closely with the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network, and other organizations that influence how cancer care is delivered through their guidelines and educational activities. Based on his contributions, he was appointed to the ASCO Quality Oncology Practice Initiative Steering Committee, which oversees selection and performance of the quality indicators used by practices for self-evaluation and reporting.



Michelle Janelsins, Ph.D., M.P.H.

Dr. Michelle Janelsins is Director of the Cancer Control and Psychoneuroimmunology Laboratory and a tenured Associate Professor in the Departments of Surgery, Radiation Oncology, and Neuroscience at the University of Rochester Medical Center. She is also a member of the Cancer Control and Survivorship Research Program at the Wilmot Cancer Institute. She is the Co-Director of the NCI R25T Clinical and Translational Cancer Control Research Training Program at Wilmot Cancer Institute and Director of Translational Science for the University of Rochester Cancer Center NCI Community Oncology Research Program (URCC NCORP) Research Base. She serves as a translational science expert for the NCI Symptom Management and Quality of Life Steering Committee, a member of the American Society for Clinical Oncology (ASCO) Scientific Program Committee in Patient and Survivor Care, and a member of the ASCO Geriatric Oncology Guidelines Committee.

Dr. Janelsins's research focuses on: 1) measurement of cancer-related cognitive impairment (CRCI), 2) understanding clinical, psychological, and biological mechanisms involved in CRCI, and 3) behavioral and pharmaceutical interventions to alleviate CRCI. Her research employs multidisciplinary clinical and preclinical research methods including approaches in cognitive and molecular neuroscience, neuropsychology, psychoneuroimmunology, immunology, genetics, epidemiology, and clinical trials. She is the PI of one of the largest longitudinal cohort studies to date investigating the trajectory of cancer-related cognitive impairment in breast cancer and lymphoma patients receiving chemotherapy compared to age-matched non-cancer controls. She is currently or has been independently funded by an NIH Director's Innovator Award (DP2), an NCI K07 Award, an NCI R21, and other grants totaling over \$5 million as Principal Investigator (PI). In addition to her main area of research in CRCI, Dr. Janelsins is also involved in several other cancer control, cancer survivorship, and neuroscience-related research projects. Dr. Janelsins has published over 75 peer-reviewed manuscripts, and her work has been honored with several outstanding research awards. Dr. Janelsins also enjoys mentoring new faculty, fellows, and students interested in transdisciplinary cancer-related research careers, having served as a mentor or co-mentor on several career development grant awards.



James Kirkland, M.D., Ph.D.

Dr. James L. Kirkland is the director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic, and is the Noaber Foundation Professor of Aging Research. Dr. Kirkland's research is on cellular senescence, age-related adipose tissue and metabolic dysfunction, and development of agents and strategies for targeting fundamental aging mechanisms to treat age-related chronic diseases and disabilities. He published the first article about drugs that clear senescent cells – senolytic agents. He is a scientific advisory board member for several companies and academic organizations. He is a member of the National Advisory Council on Aging of the National Institutes of Health, President-Elect of the American Federation for Aging Research, and past chair of the Biological Sciences Section of the Gerontological Society of America. He holds honorary appointments at Boston University and the University of Groningen in the Netherlands. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism.



Valter Longo, Ph.D

Dr. Valter Longo is the Edna M. Jones Professor of Gerontology and Biological Sciences and Director of the Longevity Institute at the University of Southern California – Davis School of Gerontology, Los Angeles. He is also a Senior Group Leader at the International Foundations of Medicine (IFOM) and holds four professorships across top EU academic centers. Dr. Longo's studies focus on the fundamental mechanisms of aging in simple organisms, mice, and humans. The Longo laboratory has identified several genetic pathways that regulate aging in simple organisms and reduce the incidence of multiple diseases in mice and humans. His laboratory also described both dietary and genetic interventions that could reverse the course of diabetes and Alzheimer's and protect cells and improve the treatment of cancer and other diseases in mammals. Dr. Longo's most recent studies are on dietary interventions that can affect stem cell-based regeneration to promote longevity in mice and humans. The Longevity Institute in Los Angeles, directed by Dr. Longo, includes over 40 faculty members focused on topics ranging from regeneration to dietary interventions aimed at improving health and lifespan in the near future. Among the accolades received by Dr. Longo are the 2010 Nathan Shock Lecture Award from the National Institute on Aging

(NIA) and the 2013 Vincent Cristofalo Rising Star Award in Aging Research from the American Federation for Aging Research (AFAR).

Dr. Longo is recognized as a global leader in aging and nutrition, with more than 106 peer-reviewed publications in journals like *Science*, *Nature*, *Cell*, *JAMA*, *Circulation*, *Cancer Cell*, and *Journal of Translational Medicine*. He was recognized by Time Magazine, with three features in less than two years, as a Longevity Guru. He is one of the most recently featured scientists by global media and news feeds.

Dr. Longo was born and raised in Genoa, Italy, and received his undergraduate degree from the University of North Texas, where he majored in biochemistry with a minor in jazz performance. He received his Ph.D. in Biochemistry from the University of California, Los Angeles (UCLA) in 1997 and completed his postdoctoral training in the Neurobiology of Aging and Alzheimer's Diseases at USC. He started his independent career in 2000 at the University of Southern California School of Gerontology, one of the first and leading programs for aging research and education.



Simin Meydani, D.V.M., Ph.D.

Dr. Simin Nikbin Meydani is Vice Provost of Research at Tufts University, Director of the Immunology Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, and Professor of Nutrition and Immunology at Tufts' Friedman School of Nutrition Science and Policy and Sackler Graduate Program in Immunology. Her scientific interests include the impact of nutrition on aging and age-associated diseases, its role in immune and inflammatory responses and predisposition to infectious diseases. She is an internationally recognized scholar with over 300 publications and continuous federal and non-federal funding. Her honors include the American Aging Association Denham Harman Lifetime Research Achievement Award; American Society for Nutrition Herman Award in clinical nutrition; ASN Lederle Award in Human Nutrition Research; Fellow of Hedwig van Amerigen Executive Leadership in Academic Medicine; American College of Nutrition Grace Goldsmith Award; and International HERMES Vitamin Research Award. She was President of the American Society for Nutrition (2014-2015) and President of the American Aging Association (2005-2006). She has served academic, government, and corporate communities as a member of grant review panels and advisory boards. She has also served on the editorial boards of several journals and chaired national and international meetings.



Christian Nelson, Ph.D.

Dr. Christian Nelson is the Chief of the Psychiatry Service and an Associate Attending Psychologist in the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center. He is also an Associate Professor of Psychology in the Department of Psychiatry at Weill Medical College of Cornell University. He specializes in the treatment of older adults with cancer and patients with genitourinary malignancies. He works with the Geriatric Disease Management team in the hospital, providing psychological support for 65+ patients, and he co-facilitates a support group aimed at patients dealing with the combined issues of cancer and aging. As the psychological liaison to the Genitourinary and Sexual Medicine services, he also helps men experiencing treatment-related sexual dysfunction, and their partners, optimize intimacy before, during, and after treatment.

Through his work with the Symptom Management, Neurocognitive, and Psychotherapy laboratories, his research interests focus on the impact of cancer upon quality of life in

geriatric and prostate cancer patients, and the development of new psychotherapies targeted at these groups. Specific areas of research have included the development of a geriatric-specific assessment measure and psychotherapy; sexual dysfunction post-cancer treatments; cognitive effects of hormonal therapy for prostate cancer patients; and distress in Black men with prostate cancer.

He is a member of the American Psychosocial Oncology Society, the International Psycho-Oncology Society, the Sexual Medicine Society of North America, and the International Society of Sexual Medicine.



Laura Niedernhofer, M.D., Ph.D.

Dr. Laura Niedernhofer recently joined the University of Minnesota to direct the new Institute on the Biology of Aging & Metabolism. She is also a Professor in the Department of Biochemistry, Molecular Biology, and Biophysics at UMN. Dr. Niedernhofer's expertise is in DNA damage and repair, progeroid syndromes, cellular senescence, and aging. Prior to moving to Minneapolis, she was at The Scripps Research Institute, where she helped spearhead identification of a new class of drugs called senolytics. Prior to Scripps, she was at the University of Pittsburgh in the NCI-Designated Comprehensive Cancer Center. Dr. Niedernhofer studied chemistry at Duke University and physiology at Georgetown University, and completed the medical scientist training program at Vanderbilt University School of Medicine. Her post-doctoral training was at Erasmus Medical Center in Rotterdam, Netherlands, training in mouse genetics with Jan Hoeijmakers. Together, they have championed the notion that DNA damage plays a key causal role in aging. Dr. Niedernhofer has served on study sections for the National Cancer Institute, National Institute of Environmental Health Sciences, and National Institute on Aging. She has been awarded for research in aging, cancer, and environmental health science and was the 2018 recipient of the Vincent Cristafolo Rising Star Award in Aging Research awarded by the American Federation for Aging Research.



Keri Schadler, Ph.D.

Dr. Keri Schadler completed her Ph.D. in Cancer Biology at UT Health MD Anderson Cancer Center Graduate School of Biomedical Sciences, followed by a postdoctoral fellowship at The University of Pennsylvania Abramson Family Cancer Research Institute. Dr. Schadler is now an Assistant Professor in Pediatrics Research at MD Anderson Cancer Center in Houston, Texas. The Schadler lab aims to identify novel methods for improving tumor blood vessel function in order to improve chemotherapy delivery and efficacy. In particular, the Schadler lab utilizes moderate exercise as a tumor vessel remodeling intervention, and studies the molecular mechanisms within endothelial cells that are regulated by exercise.



Jessica Scott, Ph.D.

Dr. Jessica Scott is an Assistant Member in the Exercise Oncology Service at Memorial Sloan Kettering Cancer Center. She received her Ph.D. in Exercise Cardiovascular Physiology at the University of British Columbia in Vancouver, Canada, and completed her Post-doctoral Fellowship at NASA Johnson Space Center (JSC) in Houston, Texas. She joined MSK in 2017 after five years as a Senior Scientist in the Exercise Physiology and Countermeasures Laboratory at JSC. Her research is focused on: 1) characterization of multisystem toxicity using exercise testing, imaging, and biomarker techniques, and 2) the efficacy of exercise to prevent and reverse toxicity.



Norman "Ned" Sharpless, M.D.

Dr. Norman E. "Ned" Sharpless was officially sworn in as the 15th director of the National Cancer Institute (NCI) on October 17, 2017. Prior to his appointment, Dr. Sharpless served as the director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, a position he held since January 2014.

Dr. Sharpless was a Morehead Scholar at UNC–Chapel Hill and received his undergraduate degree in mathematics. He went on to pursue his medical degree from the UNC School of Medicine, graduating with honors and distinction in 1993. He then completed his internal medicine residency at the Massachusetts General Hospital and a hematology/oncology fellowship at Dana-Farber/Partners Cancer Care, both of Harvard Medical School in Boston. After two years on the faculty at Harvard Medical School, he joined the faculty of the UNC School of Medicine in the Departments of Medicine and Genetics in 2002. He became the Wellcome Professor of Cancer Research at UNC in 2012.

Dr. Sharpless is a member of the Association of American Physicians, as well as the American Society for Clinical Investigation (ASCI), the nation's oldest honor society for physician–scientists, and served on the ASCI council from 2011 to 2014. He was an associate editor of *Aging Cell* and deputy editor of the *Journal of Clinical Investigation*. He has authored more than 150 original scientific papers, reviews, and book chapters, and is an inventor on 10 patents. He cofounded two clinical-stage biotechnology companies: G1 Therapeutics and HealthSpan Diagnostics.

In addition to serving as director of NCI, Dr. Sharpless is chief of the Aging Biology and Cancer Section in the National Institute on Aging's Laboratory of Genetics and Genomics, where he continues his research on the biology of the aging process that promotes the conversion of normal self-renewing cells into dysfunctional cancer cells. Dr. Sharpless has made seminal contributions to the understanding of the relationship between aging and cancer, and in the preclinical development of novel therapeutics for melanoma, lung cancer, and breast cancer.



Richard "Rick" Troiano, Ph.D.

Dr. Richard "Rick" Troiano is a Program Director in the Risk Factor Assessment Branch of the Epidemiology and Genomics Research Program in NCI's Division of Cancer Control and Population Sciences. Dr. Troiano promotes the validation and use of accelerometer-based devices in the assessment of physical activity in research and population surveillance. He is interested in promoting improved understanding of the information obtained from devices and self-reports and the analytic implications of different data sources. Dr. Troiano also supports federal efforts to promote health-enhancing physical activity, as evidenced by his detail to the Office of the Surgeon General to support development of *Step it Up! The Surgeon General's Call to Action to Promote Walking and Walkable Communities* and his service as Coordinator for the development of *2008 Physical Activity Guidelines for Americans* and co-executive secretary for the *Physical Activity Guidelines for Americans, 2nd edition*.



Jan van Deursen, Ph.D.

Dr. Jan M. van Deursen received his Ph.D. degree in Cell Biology at the University of Nijmegen, Netherlands, in 1993. In 1999, he joined the staff of Mayo Clinic, where he directs a curiosity-driven research program focused on the basic biology of cancer and aging. Dr. van Deursen also directs the transgenic and gene knockout core facility (1999-present), the senescence program of the Robert and Arlene Kogod Center on Aging (2009-2017), the cell biology program of the comprehensive cancer center (2012-present), the cancer and cell aging platform of the center for biomedical discovery (2015-present), and the Paul Glenn laboratories of senescence (2013-present). Since 2012, he has served as chair of the department of Biochemistry and Molecular Biology (2012-2020).

Over the past 20 years, Dr. van Deursen has employed and refined integrated genetic, genomic, cell biological and biochemical approaches to address how aberrancies in cell cycle progression contribute to tumor formation, with emphasis on processes involved in DNA replication and chromosome segregation. Mouse models he designed to understand how chromosomal instability drives cancer led to a series of seminal discoveries that causally linked the accumulation of senescent cells in tissues and organs to aging and the development of age-related diseases such as cancer, atherosclerosis, and osteoarthritis. His work on cellular senescence was recognized by Science Magazine as “Breakthrough of the Year Runner-up” in 2011 and 2016, and has led to the development of a new class of experimental medicines that target senescent cells in the context of various cancer treatments or the treatment of other age-related diseases.